Evidence map›Paper›PMID 40588507›Full record

ArticleNature genetics2025

Disruption of TAD hierarchy promotes LTR co-option in cancer.

Elissa W P Wong, Merve Sahin, Rui Yang, UkJin Lee, Dan Li, Yingqian A Zhan, Rohan Misra, Fanny Tomas, Nawaf Alomran, Alexander Polyzos and 18 more

Abstract read
In one paragraph

Article in Nature genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Elissa W P Wong *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Merve Sahin *Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.ORCID http://orcid.org/0000-0003-3858-8332
Rui YangComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.ORCID http://orcid.org/0000-0001-9358-9907
UkJin LeeWeill Cornell Graduate School of Medical Science, Weill Cornell Medicine, New York City, NY, USA.ORCID http://orcid.org/0000-0001-6644-4286
Dan LiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.ORCID http://orcid.org/0000-0002-8777-4580
Yingqian A ZhanCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Rohan MisraDepartment of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID http://orcid.org/0000-0002-6355-2764
Fanny TomasHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Nawaf AlomranSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York City, NY, USA.
Alexander PolyzosSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York City, NY, USA.ORCID http://orcid.org/0000-0002-2509-9698
Cindy J LeeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Tuan TrieuSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York City, NY, USA.
Alexander Martinez-FundichelySandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York City, NY, USA.ORCID http://orcid.org/0000-0002-7660-5511
Thomas WiesnerHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Andrew RosowiczHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Shuyuan ChengMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Christina LiuHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Morgan LalloCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Alexander N ShoushtariSanford I. Weill Department of Medicine, Weill Cornell Medical College, New York City, NY, USA.ORCID http://orcid.org/0000-0002-8065-4412
Taha MerghoubHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.ORCID http://orcid.org/0000-0002-1518-5111
Pierre-Jacques HamardCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.ORCID http://orcid.org/0000-0002-2484-6161
Richard KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.ORCID http://orcid.org/0000-0002-6820-5083
Ekta KhuranaSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York City, NY, USA.ORCID http://orcid.org/0000-0002-4351-7566
Effie ApostolouSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York City, NY, USA.ORCID http://orcid.org/0000-0002-8111-0863
Deyou ZhengDepartment of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID http://orcid.org/0000-0003-4354-5337
Yu ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA. cheny1@mskcc.org.ORCID http://orcid.org/0000-0002-0171-3884
Christina S LeslieComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA. lesliec@mskcc.org.ORCID http://orcid.org/0000-0002-4571-5910
Ping ChiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA. chip@mskcc.org.ORCID http://orcid.org/0000-0002-0159-5531

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0M
Targeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI William D. Tap · 2018 to 2026
$21.5M
SPORE in Soft Tissue SarcomaP50CA140146 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LADANYI, MARC · 2010 to 2014
$11.1M
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8M
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)U01CA252048 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2021 to 2025
$3.1M
Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinomaR01CA265026 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2022 to 2025
$3.0M
Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancerR01CA280657 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ping Chi · 2023 to 2026
$2.9M
An integrative approach to target lineage-specific oncogenic transcription factorDP2CA174499 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2012 to 2012
$2.6M
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancerR01CA228216 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2018 to 2022
$2.5M
Understanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistanceR01CA208100 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2017 to 2021
$2.5M
NCI NIH HHS DP2 CA174499NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA140146NCI NIH HHS P50 CA217694NCI NIH HHS R01 CA208100NCI NIH HHS R01 CA228216NCI NIH HHS R01 CA265026NCI NIH HHS R01 CA280657NCI NIH HHS U01 CA252048NCI NIH HHS U54 CA224079
6 · The paper itself

Abstract

Transposable elements (TEs) are abundant in the human genome, and they provide the source for genetic and functional diversity. Previous studies have suggested that TEs are repressed by DNA methylation and chromatin modifications. Here through integrating transcriptome and 3D genome architecture studies, we showed that haploinsufficient loss of NIPBL selectively activates alternative promoters (altPs) at the long terminal repeats (LTRs) of the TE subclasses. This activation occurs through the reorganization of topologically associating domain (TAD) hierarchical structures and the recruitment of proximal enhancers. These observations indicate that TAD hierarchy restricts transcriptional activation of LTRs that already possess open chromatin features. Perturbation of hierarchical chromatin topology can lead to co-option of LTRs as functional altPs, driving aberrant transcriptional activation of oncogenes. These data uncovered a new layer of regulatory mechanisms of TE expression and posit TAD hierarchy dysregulation as a new mechanism for altP-mediated oncogene activation and transcriptional diversity in cancer.

Indexed as

DNA Transposable ElementsNeoplasmsTerminal Repeat SequencesCell Line, TumorChromatinEnhancer Elements, GeneticGene Expression Regulation, NeoplasticGenome, HumanHumansPromoter Regions, GeneticTranscriptional ActivationChromatinDNA Transposable Elements

Identifiers

PMID40588507
PMCPMC12283374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.